Novo Nordisk partners with Anthropic to build AI capabilities across medicine development

Novo Nordisk revealed on September 16 a strategic tie-up with Anthropic, maker of the Claude AI system, aimed at transforming how the company discovers and develops drugs while modernizing internal software operations. The arrangement targets specific bottlenecks in identifying promising drug candidates and creating computational tools for interpreting biological data. Anthropic's cutting-edge language models will enhance Novo's ability to build AI-powered applications company-wide. Safeguards including strict controls over sensitive information and human review processes are embedded throughout the effort to maintain integrity and regulatory compliance. Mike Doustdar, the company's chief executive, framed this as a pivotal step toward making Novo a leader in applying artificial intelligence across the healthcare sector, adding to previous partnerships with technology firms.

1. Novo and Anthropic announced September 16, 2026 a collaboration to accelerate new medicine development
2. Companies will jointly address drug discovery challenges and develop targeted solutions for biological reasoning
3. Novo will draw on Anthropic's leading-edge AI models to build software systems with machine learning across the organization
4. The partnership embeds governance frameworks and human judgment at every stage to protect confidentiality and uphold regulatory responsibilities
5. CEO Mike Doustdar said the partnership supports Novo's aim to become the world's most AI-driven healthcare company